arcturusrx.com (ARCT) Quarterly EPS earnings growth

Symbol and logo of brand Arcturus Corp (ARCT)

Stable cash flow from licensing deals with industry behemoths supports the balance sheet of Arcturus Therapeutics (ARCT). The quarterly EPS change chart visualizes this financial stability, where the metric value stands at 46.80. LUNA technology and self-amplifying RNA enable the creation of effective vaccines with low dose volumes. However, fierce patent battles with large corporations create serious risks for the company's development.

ARCT: Arcturus Therapeutics Holdings Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/15/2026

Arcturus Therapeutics (ARCT) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Arcturus Therapeutics
Flagship merchandise of Arcturus Corp

Arcturus Therapeutics (ARCT) operates in the non-cyclical biotechnology sector, where asset value depends on patent successes. The net earnings per share trend here reflects the efficiency of capitalizing clinical developments. This indicator measures the quarterly percentage change in EPS, identifying points where growth drivers are exhausted. By analyzing the quarterly EPS growth rate, an investor can detect overvalued market expectations, allowing for a timely adjustment of the holding strategy.

Who Arcturus Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ETON: Quarterly EPS earnings growth|Kamada Ltd (KMDA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Fulcrum Tx|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth